Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial findings for nonhormonal VMS therapy generalize to everyday patients.
Real-World Evidence for Nonhormonal Treatment of Menopausal Vasomotor Symptoms
Pauline M. Maki, PhD, reviews early OPTION-VMS findings showing improvements in hot flash bother, work productivity, depression, and anxiety with fezolinetant (Veozah).
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA approves pritelivir tablets to treat lesions from HSV
2
Real-world data link fezolinetant to fewer nighttime awakenings
3
Well-woman visit upgrade, post-miscarriage ultrasound findings, cardio-obstetrics framework
4
Missed & Dismissed: The diagnostic gap starts in childhood
5